Antimicrobial resistance: Current status and future direction

被引:7
作者
Saubolle, Michael A.
机构
[1] Univ Arizona, Coll Med, Phoenix, AZ USA
[2] Banner Hlth, Div Infect Dis, Lab Sci Arizona, Sonora Quest Labs, Phoenix, AZ USA
来源
AMERICAN JOURNAL OF RHINOLOGY | 2006年 / 20卷 / 06期
关键词
D O I
10.2500/ajr.2006.20.2953
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background: Antimicrobial resistance is initiated through mutations in bacterial genes, culminating in end products that help circumvent the action of specific antimicrobial agents. Resistant mutants can proliferate under a number of circumstances but primarily through the action of selective pressure from the overuse of antimicrobial agents. Methods: The results of surveillance studies over approximately the last ten years were evaluated. Conclusion: Resistance rates in the group of microorganisms associated with respiratory tract infections had been increasing rapidly over the past 10 years, but, recently, many seem to have reached a plateau. However, newer, more invasive clones of methicillin resistant Staphylococcus aureus (MRSA), differing from health care-associated MRSA (HA-MRSA), and typically associated with community-acquisition (CA-MRSA), recently have begun to proliferate. Burgeoning use of fluoroquinolones has impacted the Gram-negative bacilli (e.g., Pseudomonas aeruginosa, Escherichia coli, and Salmonella), causing their resistance rates to approach the critical point. A better understanding of the epidemiology of resistance and responsible use of antimicrobial agents are mandatory if the continuing rates of increasing resistance are to be abrogated.
引用
收藏
页码:667 / 671
页数:5
相关论文
共 14 条
[1]  
Andremont A, 2003, ASM NEWS, V69, P601
[2]   Methicillin-resistant Staphylococcus aureus:: An evolutionary, epidemiologic, and therapeutic odyssey [J].
Deresinski, S .
CLINICAL INFECTIOUS DISEASES, 2005, 40 (04) :562-573
[3]   Antimicrobial resistance among Streptococcus pneumoniae in the United States:: Have we begun to turn the corner on resistance to certain antimicrobial classes? [J].
Doern, GV ;
Richter, SS ;
Miller, A ;
Miller, N ;
Rice, C ;
Heilmann, K ;
Beekmann, S .
CLINICAL INFECTIOUS DISEASES, 2005, 41 (02) :139-148
[4]   Pneumococcal resistance to macrolides, lincosamides, ketolides, and streptogramin B agents: Molecular mechanisms and resistance phenotypes [J].
Edelstein, PH .
CLINICAL INFECTIOUS DISEASES, 2004, 38 :S322-S327
[5]   Decreasing prevalence of β-lactamase production among respiratory tract isolates of Haemophilus influenzae in the United States [J].
Heilmann, KP ;
Rice, CL ;
Miller, AL ;
Miller, NJ ;
Beekmann, SE ;
Pfaller, MA ;
Richter, SS ;
Doern, GV .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (06) :2561-2564
[6]   Persistent macrolide resistance among group A streptococci: The lack of accomplishment after 4 decades [J].
Kaplan, EL ;
Cornaglia, G .
CLINICAL INFECTIOUS DISEASES, 2005, 41 (05) :609-611
[7]   Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US - An update [J].
Karchmer, AW .
CLINICAL INFECTIOUS DISEASES, 2004, 39 :S142-S150
[8]   Antibiotic resistance in Streptococcus pneumoniae:: What does the future hold? [J].
Nuermberger, EL ;
Bishai, WR .
CLINICAL INFECTIOUS DISEASES, 2004, 38 :S363-S371
[9]   Macrolide-resistant Streptococcus pyogenes in the United states, 2002-2003 [J].
Richter, SS ;
Heilmann, KP ;
Beekmann, SE ;
Miller, NJ ;
Miller, AL ;
Rice, CL ;
Doern, CD ;
Reid, SD ;
Doern, GV .
CLINICAL INFECTIOUS DISEASES, 2005, 41 (05) :599-608
[10]   Penicillin and macrolide resistance in pneumococcal pneumonia: Does in vitro resistance affect clinical outcomes? [J].
Rothermel, CD .
CLINICAL INFECTIOUS DISEASES, 2004, 38 :S346-S349